Institute of Clinical Medicine, University of Bergen, Bergen, Norway.
Pain Ther. 2015 Jun;4(1):51-65. doi: 10.1007/s40122-015-0033-y. Epub 2015 Mar 6.
Spinal cord injury (SCI) is an injury to the spinal cord that leads to varying degrees of motor and/or sensory deficits and paralysis. Chronic pain of both neuropathic and nociceptive type is common and contributes to reduced quality of life. The aim of the review is to provide current clinical understanding as well as discuss and evaluate efficacy of pharmacological interventions demonstrated in the clinical studies. The review was based on literature search in PubMed and Medline with words "neuropathic pain" and "spinal cord injury". The review included clinical studies and not experimental data nor case reports. A limited number of randomized and placebo-controlled studies concerning treatment options of neuropathic pain after SCI were identified. Amitriptyline, a tricyclic antidepressant and the antiepileptic drugs, gabapentin and pregabalin, are most studied with demonstrated efficacy, and considered to be the primary choice. Opioids have demonstrated conflicting results in the clinical studies. In addition, administration route used in the studies as well as reported side effects restrict everyday use of opioids as well as ketamine and lidocaine. Topical applications of capsaicin or lidocaine as well as intradermal injections of Botulinum toxin are new treatment modalities that are so far not studied on SCI population and need further studies. Non-pharmacological approaches may have additional effect on neuropathic pain. Management of pain should always be preceded by thorough clinical assessment of the type of pain. Patients need a follow-up to evaluate individual effect of applied measures. However, the applied management does not necessarily achieve satisfactory pain reduction. Further clinical studies are needed to evaluate the effect of both established and novel management options.
脊髓损伤(SCI)是一种脊髓损伤,导致不同程度的运动和/或感觉功能障碍和瘫痪。神经病理性和伤害感受性慢性疼痛很常见,并导致生活质量下降。本综述的目的是提供当前对临床的理解,并讨论和评估临床研究中显示的药物干预的疗效。该综述基于在 PubMed 和 Medline 中使用“神经病理性疼痛”和“脊髓损伤”这两个词进行的文献搜索。该综述包括临床研究,不包括实验数据或病例报告。确定了一些关于 SCI 后神经病理性疼痛治疗选择的有限数量的随机和安慰剂对照研究。阿米替林是一种三环类抗抑郁药,抗癫痫药加巴喷丁和普瑞巴林的研究最多,疗效已得到证实,被认为是首选药物。阿片类药物在临床研究中的结果存在矛盾。此外,研究中使用的给药途径以及报告的副作用限制了阿片类药物以及氯胺酮和利多卡因的日常使用。辣椒素或利多卡因的局部应用以及肉毒毒素的皮内注射是新的治疗方式,迄今为止尚未在 SCI 人群中进行研究,需要进一步研究。非药物治疗方法可能对神经病理性疼痛有额外的作用。疼痛管理应始终先进行彻底的临床疼痛类型评估。患者需要进行随访以评估所采用措施的个体效果。然而,所采用的管理措施并不一定能达到令人满意的疼痛缓解效果。需要进一步的临床研究来评估既定和新的管理选择的效果。